Inclusion Criteria:

- Brain metastases allowed provided the patient does not require anticonvulsants or
corticosteroids OR has been off them for at least 7 days prior to study entry (Brain
metastases must have been treated with cranial irradiation > 4 weeks ago OR did not
require cranial irradiation at that time)

- ECOG performance status 0-1

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,500/mcL

- Platelet count >= 100,000/mcL

- Hemoglobin >= 9.0 g/dL

- Total bilirubin =< 1.5 times upper limit of normal (ULN)

- Albumin >= 2.5 g/dL

- AST and ALT =< 1.5 times ULN

- Creatinine =< 3 mg/dL

- Oxygen saturation >= 92% on room air

- All females of childbearing potential must have a negative pregnancy test within 72
hours prior to enrolling in the study

- All sexually active females of child-bearing potential and all sexually active males
with sexual partners of child-bearing potential should practice contraception (e.g.,
barrier, hormonal, IUD) or sexual abstinence during the study and for 2 months
following completion of study therapy

- Recovered from prior therapy

- At least 7 days since any of the following:

- CYP3A4 inhibitors

- Agents with proarrhythmic potential

- Anticoagulants or medications that inhibit platelet function, including
therapeutic warfarin or heparin

- Histologically proven squamous cell carcinoma of the head and neck meeting one of the
following criteria:

- Recurrent disease after surgery and/or radiotherapy or chemoradiotherapy

- Metastatic disease

- Measurable disease as defined by RECIST criteria

- Paraffin embedded tumor tissue that is appropriate for IHC and FISH analysis must be
available OR patient must be amenable to biopsy to obtain tissue for the study

- No pleural effusion

Exclusion Criteria:

- Pregnant or nursing

- History of uncontrolled or severe medical disease which could compromise study
participation, including the following:

- Uncontrolled diabetes (fasting blood glucose > 200 mg/dL)

- Uncontrolled hypertension (systolic BP > 160 mm Hg or diastolic BP > 100 mm Hg)

- Severe infection (bacterial infection requiring IV antibiotics)

- HIV

- History of uncontrolled or severe medical disease which could compromise study
participation, including the following:

- Angina at rest

- NYHA class III or IV congestive heart failure

- Ventricular arrhythmias requiring treatment

- Neuropathy > grade 2

- Echocardiogram less than institutional normal (in patients with a history of
congestive heart failure, symptoms of congestive heart failure, or clinical evidence
suggesting impaired cardiac function)

- Chemotherapy (6 weeks for nitrosoureas or mitomycin C) or palliative radiotherapy for
recurrent and/or metastatic disease within the past 3 weeks

- Concurrent chemoradiotherapy within the past 6 weeks or failure to recover to at
least grade1 from therapy completed more than 4 weeks ago

- Concurrent treatment with any medications or substances that are potent inhibitors or
inducers of CYP3A4

- Concurrent agents with proarrhythmic potential

- Other concurrent anti-neoplastic agents (i.e., cytotoxic chemotherapy, immunotherapy,
radiotherapy, or investigational therapy) used to treat the primary disease [Local
radiotherapy (excluding radiotherapy to the target lesion) involving a small
radiation field for supportive reasons allowed]

- Any other concurrent investigational agents

- Bisphosphonate therapy during the first 8 weeks of study treatment

- Clinically significant cardiovascular disease, including the following:

- Myocardial infarction or ventricular tachyarrhythmia within the past 6 months

- Prolonged QTc > 480 msec (Fridericia correction)

- Major conduction abnormality (unless a cardiac pacemaker is present)

- Received > 1 prior chemotherapeutic regimen for recurrent or metastatic disease